Fate Therapeutics, Inc.

NASDAQ:FATE

Biotechnology

Healthcare
$1.05 -0.00%

-$0.00 today

Market cap
$122.39M
Beta
2.52
P/E (TTM)
-1.8
EPS (TTM)
-$1.08
52W Low $0.91High $2.88

Volume 1.87M

Average 2.92M

Income Statement

Follow revenue through to earnings.

Revenue

$6.65M

FY 2025 · Annual

-51.2% YoY

Operating Income

-$147.70M

FY 2025 · Annual

Net Income

-$136.31M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.85M96.3M63.53M13.63M6.65M
Cost of Revenue5.85M13.76M157.19M118.53M12.9M
Gross Profit50M82.54M(93.65M)(104.9M)(6.26M)
Gross Margin89.5%85.7%-147.4%-769.6%-94.1%
Research & Development215.52M320.45M172.6M135M107.83M
Selling, General & Admin57.32M84.23M96.86M90.64M46.52M
Operating Expenses266.99M390.93M96.86M105.38M141.45M
Depreciation & Amortization5.85M13.76M18.28M18.96M9.3M
EBITDA(206.3M)(267.96M)(142.65M)(176.58M)(127.02M)
EBITDA Margin-369.4%-278.3%-224.5%-1295.4%-1911.2%
Operating Income(216.99M)(308.39M)(190.51M)(210.28M)(147.7M)
Operating Margin-388.6%-320.2%-299.9%-1542.6%-2222.4%
Interest Income1.31M5.84M17.19M17.29M11.05M
Interest Expense00000
Other Income / Expenses4.84M26.67M29.58M24.01M11.39M
Income Before Tax(212.15M)(281.72M)(160.93M)(186.26M)(136.32M)
Pre-Tax Margin-379.9%-292.5%-253.3%-1366.5%-2051.1%
Income Tax Expense00000
Net Income(212.15M)(281.72M)(160.93M)(186.26M)(136.32M)
Net Margin-379.9%-292.5%-253.3%-1366.5%-2051.1%
EPS (Basic)(2.24)(2.91)(1.64)(1.64)(1.15)
EPS (Diluted)(2.24)(2.91)(1.64)(1.64)(1.15)
Weighted Avg Shares94.75M96.83M98.41M113.69M118.79M
Weighted Avg Shares (Diluted)94.75M96.83M98.41M113.69M118.79M

FATE Earnings Waterfall · TTM

NASDAQ:FATE · Revenue to Net Income

Key Ratios

EPS$-1.09
Gross Margin-377.3%
Net Margin-2101.6%
P/E Ratio-1.0
P/S Ratio88.0

Analysis

$6.3M of revenue converted into -$129.9M of net income for the selected period. Gross margin is -377.3% and net margin is -2101.6%, showing how much revenue survives after costs and taxes. EPS is $-1.09, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
EFFECTEFFECT filingNov 12, 2026
424B5424B5 filingNov 12, 2026
SC 13D/ASC 13D/A filingNov 9, 2026
8-KCurrent reportNov 5, 2026
S-3S-3 filingNov 5, 2026

How much revenue does FATE generate?

Fate Therapeutics, Inc. (FATE) reported $6.65M of revenue in fiscal 2025.

Is FATE profitable?

Fate Therapeutics, Inc. (FATE) reported -$136.31M of net income, with a net margin of -2051.1%.